Autor: "Hoyle M." - OpacWWW

Skocz do pozycji: 1.

Czasopismo naukowe

Szczegóły

Skocz do pozycji: 2.

Tytuł:: Historical lifetimes of drugs in England: application to value of information and cost-effectiveness analyses.
Autorzy:: Hoyle M; Peninsula Technology Assessment Group (PenTAG), Peninsular College of Medicine and Dentistry, University of Exeter, Exeter, UK. martin.hoyle@pms.ac.uk; Pokaż więcej
Źródło:: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [Value Health] 2010 Dec; Vol. 13 (8), pp. 885-92. Date of Electronic Publication: 2010 Sep 03.
Typ publikacji:: Historical Article; Journal Article
MeSH Terms:: Economics, Pharmaceutical*
Models, Theoretical*
Formularies as Topic/*history
Technology Assessment, Biomedical/*economics
Cost-Benefit Analysis/history ; England ; History, 20th Century ; History, 21st Century ; Humans ; Regression Analysis ; Time Factors

Czasopismo naukowe

Skocz do pozycji: 3.

Tytuł:: Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma.
Autorzy:: Hoyle M; Peninsula Medical School, University of Plymouth, Plymouth, UK. martin.hoyle@pms.ac.uk
Green C
Thompson-Coon J
Liu Z
Welch K
Moxham T
Stein K; Pokaż więcej
Źródło:: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [Value Health] 2010 Jan-Feb; Vol. 13 (1), pp. 55-60. Date of Electronic Publication: 2009 Sep 25.
Typ publikacji:: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:: Antineoplastic Agents/*economics
Antineoplastic Agents/*therapeutic use
Benzenesulfonates/*economics
Benzenesulfonates/*therapeutic use
Carcinoma, Renal Cell/*drug therapy
Kidney Neoplasms/*drug therapy
Pyridines/*economics
Pyridines/*therapeutic use
Carcinoma, Renal Cell/economics ; Chemotherapy, Adjuvant/economics ; Cost-Benefit Analysis ; Decision Support Techniques ; Disease Progression ; Humans ; Kidney Neoplasms/economics ; Markov Chains ; Models, Statistical ; National Health Programs ; Niacinamide/analogs & derivatives ; Phenylurea Compounds ; Quality-Adjusted Life Years ; Sorafenib ; United Kingdom

Czasopismo naukowe

Skocz do pozycji: 4.

Tytuł:: Cost-effectiveness of temsirolimus for first line treatment of advanced renal cell carcinoma.
Autorzy:: Hoyle M; Peninsula Medical School, University of Plymouth, Plymouth, UK. martin.hoyle@pms.ac.uk
Green C
Thompson-Coon J
Liu Z
Welch K
Moxham T
Stein K; Pokaż więcej
Źródło:: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [Value Health] 2010 Jan-Feb; Vol. 13 (1), pp. 61-8. Date of Electronic Publication: 2009 Sep 25.
Typ publikacji:: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:: Antineoplastic Agents/*economics
Antineoplastic Agents/*therapeutic use
Carcinoma, Renal Cell/*drug therapy
Kidney Neoplasms/*drug therapy
Sirolimus/*analogs & derivatives
Carcinoma, Renal Cell/economics ; Cost-Benefit Analysis ; Decision Support Techniques ; Humans ; Immunologic Factors/economics ; Immunologic Factors/therapeutic use ; Interferon-alpha/economics ; Interferon-alpha/therapeutic use ; Kaplan-Meier Estimate ; Kidney Neoplasms/economics ; National Health Programs ; Quality-Adjusted Life Years ; Sirolimus/economics ; Sirolimus/therapeutic use ; United Kingdom

Czasopismo naukowe

Informacja